• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

    11/14/24 5:10:48 PM ET
    $GOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GOVX alert in real time by email
    SC 13G/A 1 armistice-govx093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    GEOVAX LABS, INC.

    (Name of Issuer)

     

    Common Stock $0.001 par value

    (Title of Class of Securities)

     

    373678606

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  373678606
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    946,137
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    946,137
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    946,137
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  373678606
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    946,137
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    946,137
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    946,137
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 373678606
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    GEOVAX LABS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1900 Lake Park Drive, Suite 380

    Smyrna, Georgia 30080

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock $0.001 par value (“Shares”)

     

    Item 2.(e) CUSIP No.:

    373678606

     

    CUSIP No.  373678606
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 373678606
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 25, 2024:

    Armistice Capital, LLC - 946,137

    Steven Boyd - 946,137   

    (b) Percent of Class as of September 25, 2024:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 946,137

    Steven Boyd - 946,137  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 946,137

    Steven Boyd - 946,137

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 373678606
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 373678606
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $GOVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOVX

    DatePrice TargetRatingAnalyst
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    11/11/2024$15.00Buy
    Alliance Global Partners
    7/16/2024$20.00Buy
    ROTH MKM
    More analyst ratings

    $GOVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

      MIAMI, April 16, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayApril 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already registered, go back to t

      4/16/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

      MIAMI, April 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 81th Emerging Growth Conference on April 16 & 17, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1April 16, 2025 9:00Virtual Lobby opens.Register for the Conference. If you already register

      4/15/25 7:00:00 AM ET
      $ASBP
      $BENF
      $BNZI
      $CIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

      MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

      3/26/25 7:00:00 AM ET
      $AEMD
      $ASPI
      $ATCH
      $BNRG
      Medical/Dental Instruments
      Health Care
      Major Chemicals
      Industrials

    $GOVX
    Financials

    Live finance-specific insights

    See more
    • GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

      Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance into Phase 2 clinical trial for first recurrent head and neck cancer in the first half of 2025 GEO-MVA Mpox vaccine advancing with cGMP clinical batch anticipated during fourth quarter 2024 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter end

      11/12/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

      GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call Details To access the live conference call, participants may register here. The live audio webcast of the call will be available

      11/5/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

      Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin

      8/6/24 4:00:00 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital reiterated coverage on GeoVax Labs with a new price target

      D. Boral Capital reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $14.00 from $18.00 previously

      4/15/25 7:54:48 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners reiterated coverage on GeoVax Labs with a new price target

      Alliance Global Partners reiterated coverage of GeoVax Labs with a rating of Buy and set a new price target of $8.50 from $15.00 previously

      4/15/25 7:54:17 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners initiated coverage on GeoVax Labs with a new price target

      Alliance Global Partners initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $15.00

      11/11/24 7:40:44 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    SEC Filings

    See more
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:08:24 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:06:58 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by GeoVax Labs Inc.

      424B3 - GeoVax Labs, Inc. (0000832489) (Filer)

      5/1/25 5:05:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spencer John N Jr bought $9,800 worth of shares (10,000 units at $0.98), increasing direct ownership by 713% to 11,402 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/11/25 1:23:33 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VP, Business Development Sharkey John W. bought $5,940 worth of shares (6,000 units at $0.99), increasing direct ownership by 3,141% to 6,191 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/10/25 4:01:15 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Dodd David A bought $10,800 worth of shares (10,000 units at $1.08), increasing direct ownership by 38% to 36,661 units (SEC Form 4)

      4 - GeoVax Labs, Inc. (0000832489) (Issuer)

      4/1/25 4:46:16 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Leadership Updates

    Live Leadership Updates

    See more
    • GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

      Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci

      8/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

      Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology.  Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development

      1/8/24 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Valerie Montgomery Rice, MD, FACOG, President and CEO of Morehouse School of Medicine, Appointed Special Advisor to GeoVax

      First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear

      12/20/22 9:00:00 AM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GOVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GeoVax Labs Inc.

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      11/14/24 5:10:48 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by GeoVax Labs Inc.

      SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)

      2/14/24 3:38:25 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)

      2/10/21 3:16:30 PM ET
      $GOVX
      Biotechnology: Pharmaceutical Preparations
      Health Care